Friday, May 1, 2026

The Kim Jong Un Enigma: What Solution Will The Isolated Dictator Pick—Trump Or China?

North Korea's upcoming plenary meeting will review its five-year plan, assess economic and defense policies, and prepare for the 9th Party Congress.

Revolutionary AI Model Enhances Pediatric Emergency Care

A Korean team developed an AI model to classify pediatric emergency patients, enhancing treatment prioritization in ERs.

THE UN HAMMER Drops: Kim Jong Un Suddenly Pivots to ‘Child Care’ After 21 Years of Global Shame

North Korea claims its child policies surpass those of developed nations, countering UN human rights resolutions and emphasizing Kim Jong Un's leadership.

Tag: clinical trials

South Korean Biotech Seeks Breakthrough in $Trillion-Scale Alzheimer’s Market

AriBio's AR1001 is a promising oral Alzheimer's drug aiming for global blockbuster status by 2027, focusing on convenience and safety.

A New Hair-Growth Pathway?: JW0061 Targets GFRA1 After 7.2x Organoid Results and a 39% Animal Boost

JW Pharmaceutical's hair loss treatment JW0061 gains FDA approval for clinical trials, promising innovative growth stimulation for men and women.

JW Pharmaceutical Advances Gout Treatment with Epaminurad

JW Pharmaceutical advances its gout treatment, Epaminurad, with global trials nearing completion and U.S. patent secured for market entry.

CT-P55: How Celltrion’s New Biosimilar Approval Will Transform Clinical Trials in Europe

Celltrion receives EMA approval to reduce patient enrollment for CT-P55 trial, aiming to cut costs and duration of clinical development.

Unlocking Weight Loss: Hanmi Pharmaceutical’s Innovative H.O.P Project and the Game-Changing Epaglenatide

Hanmi Pharmaceutical is innovating obesity treatment with efpeglenatide and HM15275, focusing on tailored solutions for Korean patients.

FDA Grants Breakthrough Therapy Designation to Hanmi’s Epheglucagon: What This Means for Rare Disease Treatment

Hanmi Pharmaceutical's efpegerglucagon receives FDA Breakthrough Therapy designation for treating rare Congenital Hyperinsulinism, with Phase 2 results due soon.

SJN314: The Promising New Immunotherapy for Chronic Inflammatory Diseases in Asia

Samjin Pharmaceutical submits phase 1 trial plan for SJN314, targeting immune diseases, aiming for global partnerships in early clinical phases.

Chinese Biotech’s Rise: What’s the Standard of Global Tech Trade?

Analysts at the JPMHC noted a shift in biotech, with firms resisting sales and China emerging as a tech transfer leader.

Revolutionary mRNA Cancer Treatment Shows 49% Survival Improvement: What You Need to Know

A study shows mRNA-based cancer treatments significantly improve survival rates, marking a breakthrough in precision therapy for melanoma.

Unlocking the Future of Healthcare: How Adaptive Clinical Trials Can Transform Regenerative Medicine in Asia

The article discusses South Korea's efforts to ease regulations on regenerative medicine to improve patient access while addressing significant challenges.

Unlocking the Future: How Neuracle Science’s NS101 is Set to Revolutionize Alzheimer’s Treatment by 2030

Neuracle Science aims for a KOSDAQ listing and focuses on developing NS101 for neurological diseases, attracting global interest.

Nesuparib vs. Traditional Treatments: Will This New Dual-Target Cancer Drug Change the Game for Ovarian Cancer?

Onconic Therapeutics advances Nesuparib into Phase 2 trials for ovarian cancer, aiming to validate a novel re-maintenance therapy approach.

CKDB-501A vs. Botox: Can CKD BiO’s New Botulinum Toxin Compete in China’s Booming Market?

Jongkundang Bio has successfully completed Phase 3 trials in China's botulinum toxin market, signaling global expansion.

Revolutionizing Pharma: How LG CNS’s Agentic AI is Set to Transform Drug Development in South Korea

LG CNS expands its AI Transformation business into pharma, enhancing drug development with AI-driven platforms and automation services.

Top News

- Our Sponsors Ad -

Follow us